STAT

JANUARY 31, 2024

The descent into dementia can feel like traversing a minefield, coming across new symptoms without the hope of a cure. But some dementia patients, even up to 10% of people diagnosed with the condition, might actually have undiagnosed liver disease and accompanying neurological problems, a new study in JAMA Open Network suggests. Most importantly, it’s possible their liver-related brain symptoms could be resolved with treatment.

359

359

PharmaVoice

JANUARY 31, 2024

The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.

265

265

STAT

JANUARY 31, 2024

WILMINGTON, Del. — Wednesday was the first time that a federal judge asked questions in-person of drug industry lawyers who are trying to stop Medicare from negotiating drug prices. It didn’t go well for them. AstraZeneca’s lawyers argued that Medicare’s new powers amount to a taking of their property rights without due process.

Drug Pricing 349

Drug Pricing 349

The Pharmacist

JANUARY 31, 2024

The importance of publicising Pharmacy First has been underlined by a new survey showing that just under half (44%) of patients were unaware of the service which launches today. The poll, held by pharmacy platform Charac in partnership with YouGov, also found that only 23% of patients are currently using pharmacies as their initial port […] The post Public awareness poll highlights value of Pharmacy First promotion appeared first on The Pharmacist.

110

110

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JANUARY 31, 2024

Cigna is officially exiting the Medicare business, agreeing to sell all of its Medicare insurance plans to Health Care Service Corp., a large Blue Cross Blue Shield insurer, for $3.3 billion. The deal includes Cigna’s 600,000 Medicare Advantage plan members, as well as all Medicare beneficiaries who have a Medicare prescription drug plan and Medigap plan through Cigna.

346

346

pharmaphorum

JANUARY 31, 2024

In this exclusive interview, Gene Kinney, CEO of Prothena, discusses the latest developments in the field of neurodegenerative diseases such as Alzheimer's and Parkinson's. Gain insights and advancements being made in the treatment of these conditions.

118

118

pharmaphorum

JANUARY 31, 2024

Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.

135

135

STAT

JANUARY 31, 2024

Over the past few years, I have watched a wonderful young boy I’ll call Chad grow up smart and full of life. His parents, a gay couple with whom I am friends, used a gestational surrogate, Mary (also a pseudonym), a kind, down-to-earth woman whom I have also met. I have been thinking of him recently when I read Pope Francis’  recent comments about surrogacy.

303

303

Express Pharma

JANUARY 31, 2024

Pfizer and Glenmark Pharmaceuticals have joined hands to launch abrocitinib, an oral advanced systemic treatment for moderate-to-severe atopic dermatitis (AD), in India. Developed by Pfizer, abrocitinib has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) in India and is approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and other regulatory agencies.

105

105

STAT

JANUARY 31, 2024

The Biden administration may soon double down on one of its gravest mistakes. In 2022, it supported a petition before the World Trade Organization to gut intellectual property protections for Covid-19 vaccines. Now, with the WTO planning to take up the issue again in late February, the administration must decide whether to support a similar proposal that would strip protections from Covid-19 treatments and diagnostics as well.

Vaccines 302

Vaccines 302

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

BioPharma Dive

JANUARY 31, 2024

The agency is planning a pilot program across states to help sickle cell patients access treatments like the newly approved Casgevy and Lyfgenia.

111

111

STAT

JANUARY 31, 2024

LONDON — Novo Nordisk said Wednesday that it had started to increase the availability of its blockbuster obesity drug Wegovy for new patients in the United States, after massive demand and a supply crunch had led it to limit such doses last May. The announcement that Novo was making more of its lower-dose starter product available as of this month came as the company reported its 2023 earnings, with sales up by 36% and operating profit up 44% at constant exchange rates, driven by massive

Diabetes 295

Diabetes 295

pharmaphorum

JANUARY 31, 2024

A surge in 2023 sales and profits fuelled by diabetes and obesity drugs has driven Novo Nordisk's valuation toward $500bn

Diabetes 119

Diabetes 119

STAT

JANUARY 31, 2024

About a decade ago, Tatiana Bremova-Ertl’s graduate adviser was studying an obscure, 1950s-era French vertigo drug, probing its effects on people with balance disorders, when she thought of another, very sick group of patients.  A graduate student and medical resident at the German Center for Vertigo and Balance Disorders, in Munich, Bremova-Ertl often saw patients with Niemann-Pick Type C, a rare, genetic disease that slowly kills neurons.

Drug Development 266

Drug Development 266

PharmaTech

JANUARY 31, 2024

This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.

Dosage 98

Dosage 98

STAT

JANUARY 31, 2024

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clini

Adverse Reactions 263

Adverse Reactions Labelling Hospitals 263

BioPharma Dive

JANUARY 31, 2024

The decision to discontinue the controversial drug closes a tumultuous three-year saga that brought significant upheaval to the company.

113

113

STAT

JANUARY 31, 2024

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation and get started. Our flavor today is glazed doughnut — sweets for the sweet, you know? Meanwhile, do keep us in mind if you hear anything interesting.

Diabetes 208

Diabetes 208

pharmaphorum

JANUARY 31, 2024

Reverba offers innovative patient engagement solutions and strategies that utilise the power of authentic patient influencers. Discover the secret to successful patient influencer marketing and how it can benefit your healthcare organisation.

96

96

STAT

JANUARY 31, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with the final act in a pharmaceutical saga, the debate of Vertex Pharmaceuticals’ success, and news on 23andMe’s ongoing transformation.

Drug Pricing 204

Drug Pricing Drug Development 204

BioPharma Dive

JANUARY 31, 2024

The British drugmaker reported Arexvy sales of about $1.5 billion for 2023, higher than the range it had previously predicted for the year.

Vaccines 108

Vaccines 108

pharmaphorum

JANUARY 31, 2024

AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9 billion alliance with Genmab signed in 2020 – can be used to treat adults with DLBCL whose cancer has returned or has not responded to at least two previous systemic treatments.

91

91

The Pharmacist

JANUARY 31, 2024

Pharmacy First is unlikely to be a significant source of complications due to increased antibiotic use but evaluation of its impact will be key, according to a National Institute of Health Research (NIHR) senior investigator. Paul Little – who is also professor of primary care research at the University of Southampton – told an NIHR […] The post 'Easy access' to antibiotics 'may or may not be a good thing' appeared first on The Pharmacist.

92

92

pharmaphorum

JANUARY 31, 2024

Digital health investments has halved for the second year in a row, according to a new report from CB Insights

113

113

Outsourcing Pharma

JANUARY 31, 2024

GSK plcâs small molecule Omjjara (momelotinib), was granted marketing authorization (MA) yesterday (January 31) by the Medicines and Healthcare products Regulatory Agency (MHRA).

83

83

Pharma Times

JANUARY 31, 2024

Over 10,000 pharmacies in England will be offering the new advanced service

Community Pharmacies 121

Community Pharmacies 121

Pharmaceutical Technology

JANUARY 31, 2024

CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.

98

98

National Association of Boards of Pharmacy

JANUARY 31, 2024

Medication errors cause avoidable harm in approximately 1 in 30 patients , with 25% of these patients experiencing severe or life-threatening harm. Aiming to prevent these errors, Drug Enforcement Administration. provided prescribers with the option to use e-prescriptions for controlled substances (CS) based on an interim final rule published in 2010.

Prescription Filling 85

Prescription Filling Controlled Substances 85

pharmaphorum

JANUARY 31, 2024

GSK's RSV vaccine Arexvy outsold Pfizer's Abrysvo last year, but fourth-quarter figures suggest the gap may be narrowing.

Vaccines 93

Vaccines 93

The Pharmacist

JANUARY 31, 2024

One major employer has advised its pharmacists to ‘temporarily suspend’ the Pharmacy First service if they do not feel competent to deliver it, the Pharmacists’ Defence Association (PDA) has claimed. However, other approaches are potentially putting some pharmacists ‘under pressure’ to deliver the service prematurely, it added. The union said it was aware of ‘threats’ […] The post Multiple 'suspending' Pharmacy First if competent pharmacist unavailable appeared first on The Pharm

75

75

Pharma Times

JANUARY 31, 2024

The institute is one of two UK laboratories wholly funded by the MRC

116

116

PharmaTech

JANUARY 31, 2024

The emergence of mRNA vaccines and cell and gene therapies have pushed innovation in analytical methods.

Vaccines 98

Vaccines 98

Express Pharma

JANUARY 31, 2024

Cell And Gene Therapies: The Next Frontier? Click to download: February 2024 Digital Magazine The post Express Pharma February 2024 appeared first on Express Pharma.

72

72

Pharmafile

JANUARY 31, 2024

Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the full development and commercialisation rights to its pipeline of investigational novel immune cell therapies as well as its discovery and clinical manufacturing capabilities. Under the terms of this agreement, Regeneron is expected to acquire full […] The post Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio appeared first on Phar

Immunity 68

Immunity Immunization 68

Drug Patent Watch

JANUARY 31, 2024

Annual Drug Patent Expirations for RESTASIS Restasis is a drug marketed by Abbvie and is included in one NDA. It is available from four suppliers. There are ten patents protecting… The post New patent for Abbvie drug RESTASIS appeared first on DrugPatentWatch - Make Better Decisions.

64

64